 <h1>Crizanlizumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to crizanlizumab: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, crizanlizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking crizanlizumab:</p><p>
<i>More common</i>
</p><ul>
<li>Fever</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
<li>chest tightness</li>
<li>chills</li>
<li>dizziness</li>
<li>flushing</li>
<li>headache</li>
<li>itching skin or rash</li>
<li>nausea and vomiting</li>
<li>sweating</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of crizanlizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>difficulty with moving</li>
<li>joint pain</li>
<li>muscle pain or stiffness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to crizanlizumab: intravenous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included nausea, arthralgia, back pain, and pyrexia.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (11%)</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (18%) </p>
<p><b>Frequency not reported</b>: Oropharyngeal pain, abdominal pain, diarrhea, vomiting</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (18%), Back pain (15%) </p>
<p><b>Frequency not reported</b>: Musculoskeletal chest pain, myalgia</p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Pruritus</p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Vulvovaginal pruritus</p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Anti-drug antibodies</p><p>As with all therapeutic proteins, there is potential for immunogenicity.  The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay, and therefore, comparison of the incidence of antibodies with the incidence of antibodies in other studies may be misleading.  In a study in patients with sickle cell disease, 0 of 45 patients tested positive for anti-drug antibodies.  In a study in healthy subjects 1 of 61 patients tested positive for antidrug antibodies.</p><h3>Local</h3><p><b>Frequency not reported</b>: Infusion-site extravasation, infusion-site pain, infusion-site swelling</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Adakveo (crizanlizumab)." Novartis Pharmaceuticals, East Hanover, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about crizanlizumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>En Español</li>
<li>Drug class: miscellaneous uncategorized agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Crizanlizumab-tmca Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Adakveo</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Anemia, Sickle Cell</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to crizanlizumab: intravenous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included nausea, arthralgia, back pain, and pyrexia.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (11%)</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (18%) </p><p><b>Frequency not reported</b>: Oropharyngeal pain, abdominal pain, diarrhea, vomiting</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (18%), Back pain (15%) </p><p><b>Frequency not reported</b>: Musculoskeletal chest pain, myalgia</p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Pruritus</p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Vulvovaginal pruritus</p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Anti-drug antibodies</p><p>As with all therapeutic proteins, there is potential for immunogenicity.  The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay, and therefore, comparison of the incidence of antibodies with the incidence of antibodies in other studies may be misleading.  In a study in patients with sickle cell disease, 0 of 45 patients tested positive for anti-drug antibodies.  In a study in healthy subjects 1 of 61 patients tested positive for antidrug antibodies.</p><h3>Local</h3><p><b>Frequency not reported</b>: Infusion-site extravasation, infusion-site pain, infusion-site swelling</p><p id="ref_1">1. "Product Information. Adakveo (crizanlizumab)." Novartis Pharmaceuticals, East Hanover, NJ. </p><h2>More about crizanlizumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>En Español</li>
<li>Drug class: miscellaneous uncategorized agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Crizanlizumab-tmca Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Anemia, Sickle Cell</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>